Erica Carrier
Last active: 3/26/2019

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Hemnes AR, Rathinasabapathy A, Austin EA, Brittain EL, Carrier EJ, Chen X, Fessel JP, Fike CD, Fong P, Fortune N, Gerszten RE, Johnson JA, Kaplowitz M, Newman JH, Piana R, Pugh ME, Rice TW, Robbins IM, Wheeler L, Yu C, Loyd JE, West J (2018) Eur Respir J 51(6)
    › Primary publication · 29903860 (PubMed) · PMC6613216 (PubMed Central)
  2. rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling. Rathinasabapathy A, Bryant AJ, Suzuki T, Moore C, Shay S, Gladson S, West JD, Carrier EJ (2018) Front Physiol : 271
    › Primary publication · 29731719 (PubMed) · PMC5922219 (PubMed Central)
  3. Precision Modeling of Pulmonary Hypertension Pathology with Induced Pluripotent Stem Cell-derived Cells. West JD, Carrier EJ (2018) Am J Respir Crit Care Med 198(2): 154-155
    › Primary publication · 29596760 (PubMed) · PMC6058992 (PubMed Central)
  4. Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. Suzuki T, Carrier EJ, Talati MH, Rathinasabapathy A, Chen X, Nishimura R, Tada Y, Tatsumi K, West J (2018) Am J Physiol Lung Cell Mol Physiol 314(1): L118-L126
    › Primary publication · 28935639 (PubMed) · PMC5866427 (PubMed Central)
  5. Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. Gaskill CF, Carrier EJ, Kropski JA, Bloodworth NC, Menon S, Foronjy RF, Taketo MM, Hong CC, Austin ED, West JD, Means AL, Loyd JE, Merryman WD, Hemnes AR, De Langhe S, Blackwell TS, Klemm DJ, Majka SM (2017) J Clin Invest 127(6): 2262-2276
    › Primary publication · 28463231 (PubMed) · PMC5451236 (PubMed Central)
  6. Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload. West JD, Voss BM, Pavliv L, de Caestecker M, Hemnes AR, Carrier EJ (2016) Pulm Circ 6(2): 211-23
    › Primary publication · 27252848 (PubMed) · PMC4869926 (PubMed Central)
  7. Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. West JD, Carrier EJ, Bloodworth NC, Schroer AK, Chen P, Ryzhova LM, Gladson S, Shay S, Hutcheson JD, Merryman WD (2016) PLoS One 11(2): e0148657
    › Primary publication · 26863209 (PubMed) · PMC4749293 (PubMed Central)
  8. Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Bryant AJ, Carrick RP, McConaha ME, Jones BR, Shay SD, Moore CS, Blackwell TR, Gladson S, Penner NL, Burman A, Tanjore H, Hemnes AR, Karwandyar AK, Polosukhin VV, Talati MA, Dong HJ, Gleaves LA, Carrier EJ, Gaskill C, Scott EW, Majka SM, Fessel JP, Haase VH, West JD, Blackwell TS, Lawson WE (2016) Am J Physiol Lung Cell Mol Physiol 310(3): L249-62
    › Primary publication · 26637636 (PubMed) · PMC4838140 (PubMed Central)
  9. ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. Marriott S, Baskir RS, Gaskill C, Menon S, Carrier EJ, Williams J, Talati M, Helm K, Alford CE, Kropski JA, Loyd J, Wheeler L, Johnson J, Austin E, Nozik-Grayck E, Meyrick B, West JD, Klemm DJ, Majka SM (2014) Am J Physiol Cell Physiol 307(8): C684-98
    › Primary publication · 25122876 (PubMed) · PMC4200000 (PubMed Central)
  10. Levuglandin forms adducts with histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with DNA. Carrier EJ, Zagol-Ikapitte I, Amarnath V, Boutaud O, Oates JA (2014) Biochemistry 53(15): 2436-41
    › Primary publication · 24684440 (PubMed) · PMC4004227 (PubMed Central)
  11. Characterization of covalent adducts of nucleosides and DNA formed by reaction with levuglandin. Carrier EJ, Amarnath V, Oates JA, Boutaud O (2009) Biochemistry 48(45): 10775-81
    › Primary publication · 19824699 (PubMed) · PMC2824920 (PubMed Central)
  12. Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hill MN, Titterness AK, Morrish AC, Carrier EJ, Lee TT, Gil-Mohapel J, Gorzalka BB, Hillard CJ, Christie BR (2010) Hippocampus 20(4): 513-23
    › Primary publication · 19489006 (PubMed) · PMC2847038 (PubMed Central)
  13. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009) Psychoneuroendocrinology 34(8): 1257-62
    › Primary publication · 19394765 (PubMed) · PMC2716432 (PubMed Central)
  14. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008) J Neurochem 106(6): 2322-36
    › Primary publication · 18643796 (PubMed) · PMC2606621 (PubMed Central)
  15. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. Hill MN, Carrier EJ, Ho WS, Shi L, Patel S, Gorzalka BB, Hillard CJ (2008) Hippocampus 18(2): 221-6
    › Primary publication · 18058925 (PubMed)
  16. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. Hill MN, Barr AM, Ho WS, Carrier EJ, Gorzalka BB, Hillard CJ (2007) J Neurochem 103(1): 47-56
    › Primary publication · 17561935 (PubMed)
  17. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007) Nat Med 13(4): 492-7
    › Primary publication · 17401376 (PubMed)
  18. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Carrier EJ, Auchampach JA, Hillard CJ (2006) Proc Natl Acad Sci U S A 103(20): 7895-900
    › Primary publication · 16672367 (PubMed) · PMC1472541 (PubMed Central)
  19. Endocannabinoids in neuroimmunology and stress. Carrier EJ, Patel S, Hillard CJ (2005) Curr Drug Targets CNS Neurol Disord 4(6): 657-65
    › Primary publication · 16375683 (PubMed)
  20. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005) J Neurochem 95(2): 437-45
    › Primary publication · 16086683 (PubMed)
  21. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS, Falck JR, Cravatt BF, Hillard CJ (2005) J Lipid Res 46(2): 342-9
    › Primary publication · 15576840 (PubMed)
  22. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB (2005) Neuropsychopharmacology 30(3): 508-15
    › Primary publication · 15525997 (PubMed)
  23. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ (2004) Mol Pharmacol 65(4): 999-1007
    › Primary publication · 15044630 (PubMed)
  24. Production of hydroxyeicosatetraenoic acids and prostaglandins by a novel rat microglial cell line. Rademacher DJ, Kearn CS, Carrier EJ, Patel S, Delgado MA, Barkmeier A, Klick DE, Breese NM, Pfister SL, Nithipatikom K, Campbell WB, Hillard CJ (2004) J Neuroimmunol 149(1-2): 130-41
    › Primary publication · 15020073 (PubMed)
  25. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, Romero J (2003) J Neurosci 23(35): 11136-41
    › Primary publication · 14657172 (PubMed) · PMC6741043 (PubMed Central)
  26. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WB, Hillard CJ (2003) Br J Pharmacol 139(5): 1005-13
    › Primary publication · 12839875 (PubMed) · PMC1573928 (PubMed Central)